Efficacy and safety of nebivolol in hypertensive patients: a meta-analysis of randomized controlled trials.

ABSTRACT:

Purpose

Our meta-analysis was undertaken to evaluate the efficacy and safety of nebivolol compared with other second-generation β blockers for hypertensive patients.

Methods

We searched PubMed, the Cochrane Library, EMBASE, and Clinical Trials.gov databases for randomized controlled trials (RCTs). The efficacy endpoints included systolic blood pressure (SBP), diastolic blood pressure (DBP), reduction of SBP and DBP, heart rate (HR), and adverse events (AEs).

Findings

Eight RCTs with 1514 patients met the inclusion criteria. HR was significantly lower in patients receiving other second-generation β blockers compared with patients receiving nebivolol. There was no difference the reduction of blood pressure (SBP and DBP) or the reduction of SBP or DBP between the groups.

SUBMITTER: Liu JY 

PROVIDER: S-EPMC7588777 | biostudies-literature | 2020 Oct

REPOSITORIES: biostudies-literature